dc.contributor.author | Rosas, G | |
dc.contributor.author | Fragoso, G | |
dc.contributor.author | Ainciart, N | |
dc.contributor.author | Esquivel-Guadarrama, F | |
dc.contributor.author | Santana, A | |
dc.contributor.author | Bobes, RJ | |
dc.contributor.author | Ramirez-Pliego, O | |
dc.contributor.author | Toledo, A | |
dc.contributor.author | Cruz-Revilla, C | |
dc.contributor.author | Meneses, G | |
dc.contributor.author | Berguer, P | |
dc.contributor.author | Goldbaum, FA | |
dc.contributor.author | Sciutto, E | |
dc.date.accessioned | 2011-01-22T10:26:25Z | |
dc.date.available | 2011-01-22T10:26:25Z | |
dc.date.issued | 2006 | |
dc.identifier.issn | 1286-4579 | |
dc.identifier.uri | http://hdl.handle.net/11154/2335 | |
dc.description.abstract | Brucella lumazine synthase (BLS) has been previously used with success as a delivery system for systemic immunization against murine cysticercosis. We herein determined the usefulness of BLS as a new antigen-delivery system and mucosal-adjuvant using KETc1, one of the peptides of the anti-cysticercosis vaccine. A protection of up to 98% was induced when KETc1 was used as a chimera fused to BLS. Used as adjuvant of KETc1, BLS also induced a high level of protection (79%), which did not significantly differ from that induced by the cholera toxin (74%). KETc1 and BLS administered separately also reduced the parasite load. KETc1 administered orally as a chimera, and to a lesser extent with BLS as adjuvant, elicited IgG and IgA specific antibodies, which were detectable both in fecal extracts and in sera, and increased B and CD4 activated cells. BLS-KETc1 also increased the levels of transcription of TNF-alpha, IL-2 and IFN gamma in Peyer's patches, and in spleen, only increased TNF-alpha was observed. Overall, these results showed that BLS can be used as both an antigen-carrier and as an adjuvant in the design of new oral subunit vaccines. (c) 2006 Elsevier SAS. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.title | Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity | en_US |
dc.type | Article | en_US |
dc.identifier.idprometeo | 1389 | |
dc.identifier.doi | 10.1016/j.micinf.2005.12.006 | |
dc.source.novolpages | 8(5):1277-1286 | |
dc.subject.wos | Immunology | |
dc.subject.wos | Microbiology | |
dc.subject.wos | Virology | |
dc.description.index | WoS: SCI, SSCI o AHCI | |
dc.subject.keywords | oral vaccine | |
dc.subject.keywords | mucosal immunity | |
dc.subject.keywords | antigen delivery | |
dc.subject.keywords | adjuvant | |
dc.subject.keywords | lumazine synthase | |
dc.relation.journal | Microbes and Infection |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |